Síntese de complexos de Mn(III) à base de porfirinas tricatiônicas do Tipo A3B (A = 2-N-metilpiridinio; B = 3-metoxi-4-hidroxifenil ou 3,4-dimetoxifenil) como potenciais mímicos das enzimas superóxido dismutases (SOD)
Ano de defesa: | 2016 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal da Paraíba
Brasil Química Programa de Pós-Graduação em Química UFPB |
Programa de Pós-Graduação: |
Não Informado pela instituição
|
Departamento: |
Não Informado pela instituição
|
País: |
Não Informado pela instituição
|
Palavras-chave em Português: | |
Link de acesso: | https://repositorio.ufpb.br/jspui/handle/tede/8985 |
Resumo: | The superoxide anion is among the reactive oxygen species closely related to physiopathological states associated with oxidative stress. The physiological superoxide levels are controlled in vivo by the superoxide dismutase enzymes (SOD). Pentacationic Mn porphyrins derived from 2-N-alkylpyridylporphyrins have been explored as potent SOD mimics and efficient redox modulators of oxidative stress. The in vivo efficiency of these compounds is related with their intrinsic catalytic activity, lipophilicity, bioavailability, and toxicity. The present study describes the synthesis of two A3B-type neutral porphyrins of low symmetry (A = 2-pyridyl, B = 3-methoxy-4-hydroxyphenyl or 3,4-dimethoxyphenyl), the methylation of these compounds to yield tricationic porphyrins and the preparation of the corresponding tetracationic Mn(III) porphyrins; overall, 8 new compounds are described: 5-(3-methoxy-4-hydroxyphenyl)-10,15,20-tris(2-pyridyl)porphyrin (H2VanTri-2-PyP), 5-(3,4-dimethoxyphenyl)-10,15,20-tris(2-pyridyl)porphyrin (H2MVanTri-2-PyP), 5-(3-methoxy-4-hydroxyphenyl)-10,15,20-tris(N-methylpiridinium-2-yl)porphyrin chloride (H2VanTriM-2-PyPCl3), 5-(3,4-dimethoxyphenyl)-10,15,20-tris(N-methylpiridinium-2-yl)porphyrin chloride (H2MVanTriM-2-PyPCl3), 5-(3-methoxy-4-hydroxyphenyl)-10,15,20-tris(2-pyridyl)porphinatomanganese(III) (MnVanTri-2-PyPCl), 5-(3,4-dimethoxyphenyl)-10,15,20-tris(2-pyridyl)porphinatomanganese(III) chloride (MnMVanTri-2-PyPCl), 5-(3-methoxy-4-hydroxyphenyl)-10,15,20-tris(N-methylpiridinium-2-yl)porphinatomanganese(III) chloride (MnVanTriM-2-PyPCl4) and 5-(3,4-dimethoxyphenyl)-10,15,20-tris(N-methylpiridinium-2-yl)porphinatomanganese(III) chloride (MnMVanTriM-2-PyPCl4). The spectroscopic, electrochemical properties and lipophilicity of all compounds were compared with A4-type 2-N-pyridyl porphyrin analogues. The monocationic compounds MnVanTri-2-PyP+ and MnMVanTri-2-PyP+ showed too low Mn(III)/Mn(II) reduction potential incompatible with superoxide dismuting activity, whereas the tetracationic complexes MnVanTriM-2-PyP4+ and MnMVanTriM-2-PyP4+ showed potential values suitable for the development these compounds as SOD mimics based on structure-activity relationships reported for analogous systems. The lipophilicity of MnVanTriM-2-PyP4+ and da MnMVanTriM-2-PyP4+ suggests promising bioavailability for in vitro and in vivo testing. |